Axordia collaborates with Lombard Medical Technologies PLC for the development of treatment of Coronary Artery Disease
08-Aug-2006
The stent shall represent a major step forward into a new format for stent technology where early healing (endothelialisation) is promoted rather than using cytotoxic drugs on drug eluting stents (DES) which inhibit growth and can cause late stage thrombotic events. As a result this stent technology could revolutionise the DES market, according to Axordia.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.